MX2007002381A - Producci??n del receptor del factor de necrosis de tumor-prote??na de fusi??n de inmunoglobulina. - Google Patents
Producci??n del receptor del factor de necrosis de tumor-prote??na de fusi??n de inmunoglobulina.Info
- Publication number
- MX2007002381A MX2007002381A MX2007002381A MX2007002381A MX2007002381A MX 2007002381 A MX2007002381 A MX 2007002381A MX 2007002381 A MX2007002381 A MX 2007002381A MX 2007002381 A MX2007002381 A MX 2007002381A MX 2007002381 A MX2007002381 A MX 2007002381A
- Authority
- MX
- Mexico
- Prior art keywords
- cumulative
- culture
- amino acid
- glutamine
- molar
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 230000001186 cumulative effect Effects 0.000 abstract 9
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract 2
- 235000009582 asparagine Nutrition 0.000 abstract 2
- 230000007423 decrease Effects 0.000 abstract 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 150000001508 asparagines Chemical class 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000012136 culture method Methods 0.000 abstract 1
- 229910001410 inorganic ion Inorganic materials 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
Abstract
Se provee un sistema mejorado para la produccion a gran escala de una proteina de fusion dimerica que consiste de la porcion de union a ligando extracelular del receptor del factor de necrosis de tumor (TNFR) humano (p75) unido a la porcion Fc de IgGI en el cultivo de celulas, en particular, en medios caracterizados por una o mas de: (i) una concentracion acumulada de aminoacidos mayor que aproximadamente 70 nM; (ii) una relacion molar de glutamina acumulada a asparagina acumulada inferior a aproximadamente 2; (iii) una relacion molar de glutamina acumulada a aminoacidos totales cumulados inferior a aproximadamente 0.2; (iv) una relacion molar de ion inorganico acumulado a aminoacidos totales acumulados de entre alrededor de 0.4 y 1; o (v) una concentracion combinada de glutamina acumulada y asparagina acumulada de entre aproximadamente 16 y 36 mM. El uso de dicho sistema permite altos niveles de produccion de proteina, y disminuye la acumulacion de ciertos factores indeseables, tales como amonio y/o lactato. Adicionalmente, se proveen metodos de cultivo que incluyen un cambio de temperatura, que habitualmente comprende una disminucion en la temperatura cuando el cultivo ha alcanzado alrededor de 20-80% de su densidad celular maxima. Alternativa o adicionalmente, la presente invencion provee metodos tales que, despues de alcanzar un pico, los niveles de lactato y/o amonio en el cultivo disminuyen con el tiempo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60537904P | 2004-08-27 | 2004-08-27 | |
| PCT/US2005/030439 WO2006026447A2 (en) | 2004-08-27 | 2005-08-26 | PRODUCTION OF TNFR-Ig FUSION PROTEIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007002381A true MX2007002381A (es) | 2007-06-15 |
Family
ID=35500648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007002381A MX2007002381A (es) | 2004-08-27 | 2005-08-26 | Producci??n del receptor del factor de necrosis de tumor-prote??na de fusi??n de inmunoglobulina. |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US7300773B2 (es) |
| EP (2) | EP1781802B1 (es) |
| JP (3) | JP2008511330A (es) |
| KR (1) | KR100988451B1 (es) |
| CN (2) | CN101061231B (es) |
| AR (2) | AR050537A1 (es) |
| AT (2) | ATE461285T1 (es) |
| AU (1) | AU2005280036B2 (es) |
| BR (1) | BRPI0514694B8 (es) |
| CA (1) | CA2578138C (es) |
| CL (1) | CL2017000577A1 (es) |
| CR (2) | CR8998A (es) |
| CY (2) | CY1109721T1 (es) |
| DE (2) | DE602005020076D1 (es) |
| DK (2) | DK1992697T3 (es) |
| EC (1) | ECSP077354A (es) |
| EG (1) | EG26922A (es) |
| ES (2) | ES2341390T3 (es) |
| GT (2) | GT200500233A (es) |
| HK (2) | HK1121497A1 (es) |
| HN (1) | HN2005000485A (es) |
| HR (2) | HRP20100011T1 (es) |
| IL (1) | IL181588A (es) |
| MX (1) | MX2007002381A (es) |
| MY (1) | MY137803A (es) |
| NO (1) | NO344785B1 (es) |
| NZ (1) | NZ579208A (es) |
| PE (2) | PE20100448A1 (es) |
| PL (2) | PL1781802T3 (es) |
| PT (2) | PT1781802E (es) |
| RS (2) | RS51255B (es) |
| RU (1) | RU2458988C2 (es) |
| SI (2) | SI1992697T1 (es) |
| SV (1) | SV2006002211A (es) |
| TW (1) | TWI364458B (es) |
| UA (1) | UA89383C2 (es) |
| WO (1) | WO2006026447A2 (es) |
| ZA (1) | ZA200701672B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI384069B (zh) * | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS |
| PE20070796A1 (es) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| US20070231895A1 (en) * | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
| CN101541950A (zh) * | 2006-07-13 | 2009-09-23 | 惠氏公司 | 糖蛋白的产生 |
| MX2009004519A (es) * | 2006-11-03 | 2009-05-12 | Wyeth Corp | Sustancias que inhiben la glucolisis en un cultivo de celulas. |
| KR101523782B1 (ko) * | 2006-11-08 | 2015-05-28 | 와이어쓰 엘엘씨 | 세포 배양을 위한 합리적으로 설계된 배지 |
| DK2115126T3 (en) * | 2007-03-02 | 2015-05-04 | Wyeth Llc | Use of copper and glutamate in cell culture for the preparation of polypeptides |
| TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| WO2008136398A1 (ja) | 2007-04-26 | 2008-11-13 | Chugai Seiyaku Kabushiki Kaisha | 高濃度アミノ酸含有培地を用いた細胞の培養方法 |
| US8039231B2 (en) * | 2008-04-17 | 2011-10-18 | Wyeth Llc | Methods for enhanced production of bone morphogenetic proteins |
| BRPI0822597A2 (pt) * | 2008-04-18 | 2019-09-24 | Shanghai Cp Guojian Pharmaceutical Co Ltd | meio concetrado e sua utilização |
| US8318416B2 (en) | 2008-08-08 | 2012-11-27 | Biogen Idec Ma Inc. | Nutrient monitoring and feedback control for increased bioproduct production |
| EP3760712A1 (en) | 2009-08-11 | 2021-01-06 | F. Hoffmann-La Roche AG | Production of proteins in glutamine-free cell culture media |
| CA2782320A1 (en) * | 2009-12-02 | 2011-06-09 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life of fc fusion proteins |
| PL3330370T3 (pl) | 2010-04-26 | 2021-09-20 | Novartis Ag | Sposób hodowania komórek cho |
| AU2011246504B2 (en) | 2010-04-26 | 2013-09-26 | Novartis Ag | Improved cell culture medium |
| WO2012023085A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
| WO2012068134A1 (en) | 2010-11-15 | 2012-05-24 | Biogen Idec Inc. | Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography |
| MY169935A (en) | 2011-04-29 | 2019-06-18 | Biocon Biologics India Ltd | "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof" |
| US8883982B2 (en) | 2011-06-08 | 2014-11-11 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
| US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
| WO2013059406A1 (en) | 2011-10-18 | 2013-04-25 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with metal ions |
| KR20170021919A (ko) * | 2011-10-21 | 2017-02-28 | 화이자 인코포레이티드 | 철을 첨가하여 세포 배양을 개선하는 방법 |
| NZ629309A (en) * | 2012-02-22 | 2016-03-31 | Nvip Pty Ltd | Tumour necrosis factor receptor fusion proteins and methods of using the same |
| EP2869817A4 (en) | 2012-07-09 | 2016-04-06 | Coherus Biosciences Inc | STABLE AQUEOUS FORMULATIONS OF ETANERCEPT |
| BR112015005161A2 (pt) | 2012-09-11 | 2017-07-04 | Coherus Biosciences Inc | etanercepte corretamente dobrado em alta pureza e excelente rendimento |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| AU2014241259B9 (en) | 2013-03-26 | 2018-12-20 | Coherus Biosciences, Inc. | Protein production method |
| KR101439195B1 (ko) | 2013-04-18 | 2014-09-12 | 동아대학교 산학협력단 | 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정 |
| US11390663B2 (en) | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
| KR102510238B1 (ko) * | 2013-10-11 | 2023-03-16 | 리제너론 파마슈티칼스 인코포레이티드 | 대사적으로 최적화된 세포 배양 |
| JP6749838B2 (ja) | 2014-01-30 | 2020-09-02 | コヒラス・バイオサイエンシズ・インコーポレイテッド | かん流培地 |
| US20160347787A1 (en) | 2014-02-04 | 2016-12-01 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| WO2016089919A1 (en) | 2014-12-01 | 2016-06-09 | Amgen Inc. | Process for manipulating the level of glycan content of a glycoprotein |
| KR102007930B1 (ko) | 2014-12-31 | 2019-08-06 | 주식회사 엘지화학 | 재조합 당단백질의 글리코실화 조절 방법 |
| CN105777897A (zh) * | 2015-03-20 | 2016-07-20 | 广东东阳光药业有限公司 | 一种cho细胞收获液的前处理方法 |
| KR20170140251A (ko) * | 2015-04-01 | 2017-12-20 | 베링거 인겔하임 인터내셔날 게엠베하 | 세포 배양 배지 |
| KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
| BR112019007858A2 (pt) | 2016-10-21 | 2019-07-02 | Amgen Inc | formulações farmacêuticas e métodos para produzir as mesmas |
| CN110484487A (zh) * | 2019-08-21 | 2019-11-22 | 安徽欣乐生物技术有限公司 | 一种适用于cho细胞培养用无蛋白培养基及其培养方法 |
| JP2024503239A (ja) | 2020-12-22 | 2024-01-25 | アムジェン インコーポレイテッド | 細胞培養法 |
| CN115073607A (zh) * | 2021-03-12 | 2022-09-20 | 上海康岱生物医药技术股份有限公司 | Tnfr2与baff受体的融合蛋白 |
| CN114480492B (zh) * | 2022-01-28 | 2023-04-21 | 景泽生物医药(合肥)股份有限公司 | 一种重组人抗体融合蛋白的制备方法 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| ATE135397T1 (de) * | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
| DK0939121T4 (da) | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
| CA2067194C (en) | 1989-10-05 | 2003-03-18 | Glenn Kawasaki | Cell-free synthesis and isolation of novel genes and polypeptides |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5538983A (en) | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| US5156964A (en) | 1990-08-16 | 1992-10-20 | Cetus Corporation | Methods for adapting cells for increased product production through exposure to ammonia |
| US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| GB2251249B (en) | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
| GB9118664D0 (en) | 1991-08-30 | 1991-10-16 | Celltech Ltd | Cell culture |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| JP3504963B2 (ja) | 1993-10-22 | 2004-03-08 | 智靖 羅 | 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片 |
| US6310185B1 (en) | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
| US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| US5589154A (en) | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US6656466B1 (en) * | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
| US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| JP4306813B2 (ja) | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
| US20020012991A1 (en) | 1997-04-07 | 2002-01-31 | Florence Chua Nee Ho Kit Fong | Cell culture media for enhanced protein production |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| CA2354862A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| AU2002257162A1 (en) | 2001-04-30 | 2002-11-11 | Eli Lilly And Company | Humanized antibodies |
| DE60230736D1 (de) | 2001-04-30 | 2009-02-26 | Lilly Co Eli | HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9; |
| US20030087372A1 (en) | 2001-06-13 | 2003-05-08 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| JP4429729B2 (ja) | 2002-02-21 | 2010-03-10 | ワイス エルエルシー | Ｇａｓｐ１；フォリスタチンドメイン含有タンパク質 |
| WO2003072714A2 (en) | 2002-02-21 | 2003-09-04 | Wyeth | Follistatin domain containing proteins |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| LT1507556T (lt) | 2002-05-02 | 2016-10-10 | Wyeth Holdings Llc | Kalicheamicino darinio ir nešiklio konjugatai |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
-
2005
- 2005-08-25 TW TW094129077A patent/TWI364458B/zh not_active IP Right Cessation
- 2005-08-25 US US11/213,633 patent/US7300773B2/en active Active
- 2005-08-26 WO PCT/US2005/030439 patent/WO2006026447A2/en active Application Filing
- 2005-08-26 DK DK08005732.6T patent/DK1992697T3/da active
- 2005-08-26 ES ES08005732T patent/ES2341390T3/es active Active
- 2005-08-26 PE PE2009001227A patent/PE20100448A1/es active IP Right Grant
- 2005-08-26 SV SV2005002211A patent/SV2006002211A/es unknown
- 2005-08-26 PT PT05791482T patent/PT1781802E/pt unknown
- 2005-08-26 AT AT08005732T patent/ATE461285T1/de active
- 2005-08-26 MX MX2007002381A patent/MX2007002381A/es active IP Right Grant
- 2005-08-26 PT PT08005732T patent/PT1992697E/pt unknown
- 2005-08-26 EP EP05791482A patent/EP1781802B1/en not_active Revoked
- 2005-08-26 AU AU2005280036A patent/AU2005280036B2/en active Active
- 2005-08-26 CN CN2005800369388A patent/CN101061231B/zh not_active Expired - Fee Related
- 2005-08-26 DE DE602005020076T patent/DE602005020076D1/de active Active
- 2005-08-26 MY MYPI20054023A patent/MY137803A/en unknown
- 2005-08-26 RS RSP-2010/0190A patent/RS51255B/sr unknown
- 2005-08-26 DE DE602005017285T patent/DE602005017285D1/de active Active
- 2005-08-26 AT AT05791482T patent/ATE446376T1/de active
- 2005-08-26 ES ES05791482T patent/ES2335518T3/es active Active
- 2005-08-26 HN HN2005000485A patent/HN2005000485A/es unknown
- 2005-08-26 GT GT200500233A patent/GT200500233A/es unknown
- 2005-08-26 CN CN2012102771283A patent/CN102876761A/zh active Pending
- 2005-08-26 SI SI200530984T patent/SI1992697T1/sl unknown
- 2005-08-26 EP EP08005732A patent/EP1992697B1/en not_active Revoked
- 2005-08-26 DK DK05791482.2T patent/DK1781802T3/da active
- 2005-08-26 PL PL05791482T patent/PL1781802T3/pl unknown
- 2005-08-26 PE PE2005000987A patent/PE20060815A1/es not_active Application Discontinuation
- 2005-08-26 KR KR1020077004810A patent/KR100988451B1/ko active IP Right Grant
- 2005-08-26 NZ NZ579208A patent/NZ579208A/en not_active IP Right Cessation
- 2005-08-26 AR ARP050103596A patent/AR050537A1/es not_active Application Discontinuation
- 2005-08-26 JP JP2007530167A patent/JP2008511330A/ja active Pending
- 2005-08-26 RU RU2007108717/10A patent/RU2458988C2/ru active
- 2005-08-26 BR BRPI0514694A patent/BRPI0514694B8/pt active IP Right Grant
- 2005-08-26 GT GT200500234A patent/GT200500234A/es unknown
- 2005-08-26 UA UAA200703287A patent/UA89383C2/ru unknown
- 2005-08-26 PL PL08005732T patent/PL1992697T3/pl unknown
- 2005-08-26 CA CA2578138A patent/CA2578138C/en active Active
- 2005-08-26 SI SI200530874T patent/SI1781802T1/sl unknown
- 2005-08-26 RS RSP-2009/0575A patent/RS51072B/sr unknown
-
2007
- 2007-02-26 ZA ZA2007/01672A patent/ZA200701672B/en unknown
- 2007-02-27 EG EGNA2007000222 patent/EG26922A/xx active
- 2007-02-27 IL IL181588A patent/IL181588A/en unknown
- 2007-03-16 CR CR8998A patent/CR8998A/es unknown
- 2007-03-26 NO NO20071570A patent/NO344785B1/no not_active IP Right Cessation
- 2007-03-27 EC EC2007007354A patent/ECSP077354A/es unknown
- 2007-07-16 HK HK09102060.2A patent/HK1121497A1/xx not_active IP Right Cessation
- 2007-07-16 HK HK07107585.9A patent/HK1099941A1/xx not_active IP Right Cessation
-
2010
- 2010-01-08 CY CY20101100022T patent/CY1109721T1/el unknown
- 2010-01-11 HR HR20100011T patent/HRP20100011T1/hr unknown
- 2010-05-14 HR HR20100271T patent/HRP20100271T1/hr unknown
- 2010-06-16 CY CY20101100556T patent/CY1110092T1/el unknown
-
2012
- 2012-02-17 JP JP2012033112A patent/JP5921910B2/ja active Active
- 2012-11-01 CR CR20120560A patent/CR20120560A/es unknown
- 2012-11-09 AR ARP120104234A patent/AR088824A2/es not_active Application Discontinuation
-
2016
- 2016-01-28 JP JP2016014650A patent/JP2016056214A/ja active Pending
-
2017
- 2017-03-09 CL CL2017000577A patent/CL2017000577A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007002381A (es) | Producci??n del receptor del factor de necrosis de tumor-prote??na de fusi??n de inmunoglobulina. | |
| TW200615379A (en) | Production of α-abeta | |
| SG158092A1 (en) | Production of polypeptides | |
| US10981990B2 (en) | Antibody molecules to TIM-3 and uses thereof | |
| KR101110547B1 (ko) | 인간화 ｃ-ｋｉｔ 항체 | |
| EP2970423B1 (en) | Interleukin-2 muteins for the expansion of t-regulatory cells | |
| SG10201408063SA (en) | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof | |
| EA035160B1 (ru) | Антитела к st2 и их применение | |
| JP2017140056A (ja) | オンコスタチンｍ受容体抗原結合タンパク質 | |
| IN2015DN02553A (es) | ||
| AU2010230311B2 (en) | Composition and methods of use for therapeutic antibodies specific for the IL-12 receptore betal subunit | |
| TW200950778A (en) | Methods of using Apo2L/TRAIL to treat cancer | |
| WO2014145091A1 (en) | Cell culture media and methods of antibody production | |
| WO2008060814A3 (en) | ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF | |
| Watanabe et al. | Analysis of temperature effects on seasonal and interannual variation in CH4 emission from rice-planted pots | |
| EP2488200A1 (en) | April antagonists and methods of use | |
| JP5768341B2 (ja) | Ｆｃ結合性タンパク質の製造方法 | |
| Morris | Biogeochemical Consequences of Converting Corn into Rice Fields: An Analysis of Greenhouse Gas (CH 4 and N 2 O) Emissions in the Sacramento-San Joaquin Delta, California | |
| ES2665596T3 (es) | Uso de compuestos intermedios de ácido tricarboxílico (ATC) para controlar la generación de amoníaco en cultivo celular | |
| Rakovic | Long-term trends in bottom water chemistry of Swedish lakes | |
| Tornblom | Microbial activity and biomass in aquatic surface sediments: A community-level approach. | |
| Zelikova et al. | COS 31-3: Biogeochemical consequences of moss die-off in response to increased pulsing precipitation in an arid ecosystem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights | ||
| GD | Licence granted |